Remove Clinical Development Remove Download Remove Marketing
article thumbnail

FSP Engagements Continue to Gain Popularity, Drive Success

PPD

A large majority of drug developers utilize FSP or hybrid FSP/FSO models, half are “heavy users” Heavy users: Those that use FSP or hybrid FSP/FSO models for most of their clinical development outsourcing. Heavy users leverage these models for nearly three-quarters of their outsourcing.

article thumbnail

Reimagining CRO Partnerships: The Emerging Preference for Midsize Organizations

Conversations in Drug Development Trends

The Advantages of Midsize CROs In contrast to large CROs, midsize CROs like Worldwide Clinical Trials offer a unique value proposition to the market. To gain deeper insights into this pivotal shift and how it can benefit your clinical development strategy, we invite you to download our full industry survey report.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Evolution of Clinical Operations Drives FSP Staffing Models to the Forefront

PPD

To support these functions, PPD™ Functional Service Partnership (FSP) Clinical Operations solutions harness the full range of innovative technologies, applying extensive skill and expertise to empower our customers to bring therapies to market quickly and within budget.

article thumbnail

Seven Strategies to Avoid Common Pitfalls in Vaccine Development

PPD

It is imperative that the right vaccine development partner demonstrates expertise from early clinical development to study design, execution, regulatory submission and commercialization. Working with a vertically integrated organization can further accelerate market entry.

Vaccine 52
article thumbnail

Navigating the Global Clinical Landscape: CTA or IND for Your First-in-Human Study?

Conversations in Drug Development Trends

Understanding the nuances of each pathway is crucial for small to midsize companies aiming to navigate the complexities of global clinical development successfully. For additional insights, download our full white paper, “ First-in-Human Studies: IND or CTA? ”.

article thumbnail

Cyxone has filed an IND in the US with Rabeximod following positive feed-back from pre-IND meeting with the FDA

The Pharma Data

The IND covers the development of Rabeximod in Covid-19 and other indications, such as rheumatoid arthritis, and is a prerequisite for a future validation of the company’s five recent patent applications in the US market. “Filing an IND with the FDA is an important step in the clinical development of Rabeximod.

FDA 52
article thumbnail

Alume Receives SBIR Phase II Grant from the NIH to Support Clinical Trial of ALM-488 to Highlight Nerves in Patients Undergoing Head & Neck Surgery

The Pharma Data

This grant will support Alume’s clinical development of its novel nerve illumination technology in surgery. Program grants are awarded to companies with promising technologies that have a strong potential for commercialization, to help translate life-saving innovations to consumer markets and create jobs in biotechnology.